866-997-4948(US-Canada Toll Free)

Bone Cancer - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Mar 2013

Category :

Cancer

No. of Pages : 162 Pages


Global Markets Directs, \'Bone Cancer Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Bone Cancer, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Cancer. 

Bone Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Bone Cancer.
  • A review of the Bone Cancer products under development by companies and universities/research institutes based on information derived from company and industry -specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Bone Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Bone Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter -strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Bone Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in -licensing and out -licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Bone Cancer Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Bone Cancer 11
Bone Cancer Therapeutics under Development by Companies 13
Bone Cancer Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Discovery and Pre -Clinical Stage Products 21
Comparative Analysis 21
Bone Cancer Therapeutics - Products under Development by Companies 22
Bone Cancer Therapeutics - Products under Investigation by Universities/Institutes 24
Companies Involved in Bone Cancer Therapeutics Development 25
Celsion Corporation 25
Amgen Inc. 26
Merck & Co., Inc. 27
Exelixis, Inc. 28
Bayer AG 29
Medivir AB 30
Osteologix, Inc. 31
Green Cross Corporation 32
Merrion Pharmaceuticals Plc 33
Digna Biotech, S.L. 34
Debiopharm Group 35
Amura Holdings Ltd. 36
Alethia Biotherapeutics Inc. 37
Hawthorn Pharmaceuticals, Inc. 38
Deciphera Pharmaceuticals, LLC 39
Virobay Inc. 40
Targa Therapeutics Corp. 41
Bone Cancer - Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Combination Products 43
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
denosumab - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
denosumab - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
denosumab - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ridaforolimus - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
ridaforolimus - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Debio -0719 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
P -17 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
disitertide - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
cabozantinib - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
doxorubicin - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
radium Ra 223 dichloride - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
VBY -825 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
MIV -711 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
zoledronic acid - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
BMTP -11 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
zoledronic acid - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
MLN -1202 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Angiotensin 1 -7 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Proline Rich Polypeptide - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Alpharadin + [docetaxel] - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
zoledronic acid + [cisplatin] + [docetaxel] - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
everolimus - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
AB -25E9 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
AM -3701 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
irinotecan hydrochloride + [docetaxel] - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
VEGF/rGel - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
MG -1102 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
DCC -2909 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
AC -301 - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
KPT -330 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
CBI -101 - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Secreted Phosphoprotein 24 KDa - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
KN -013 - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
MN -1 - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
DP -6790 - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
Bone Cancer Therapeutics - Drug Profile Updates 106
Bone Cancer Therapeutics - Discontinued Products 151
Bone Cancer Therapeutics - Dormant Products 152
Bone Cancer - Product Development Milestones 155
Featured News & Press Releases 155
Oct 23, 2012: Amgen\'s Xgeva Obtains Approval From NICE For Eligibility To NHS Funding 155
Sep 17, 2012: Bayer To Present Data On Alpharadin At ESMO 2012 Congress 155
Sep 12, 2012: Indian Supreme Court Asks Novartis To Scale Down Price Of Cancer Drug Glivec 156
Aug 21, 2012: Medivir Commences Phase Ib Trial Of MIV -711 For Treatment Of Skeletal Disorders 156
Aug 17, 2012: NICE Recommends Amgen\'s Denosumab For Most Cancer Patients With Bone Metastases In Final Draft Guidance 156
Aug 14, 2012: Denosumab Superior To Zoledronic Acid For Breast Cancer Patients With Bone Metastases, Study Finds 157
Aug 07, 2012: Philips And Celsion Announce FDA Clearance To Commence Phase II Study Of ThermoDox And MR -Guided HIFU In Bone Cancer 158
Jul 19, 2012: Novartis Files Lawsuit Against Sun Pharma For Generic Zometa, Reclast 159
Jun 18, 2012: Infinity Pharma Stops Phase II Trials Of Saridegib In Chondrosarcoma And Myelofibrosis 159
Jun 11, 2012: NICE Opens Second Consultation On Treatment For Bone Metastases In Some Cancer Patients 160

Appendix 161
Methodology 161
Coverage 161
Secondary Research 161
Primary Research 161
Expert Panel Validation 161
Contact Us 162
Disclaimer 162

List of Table


Number of Products Under Development for Bone Cancer, H1 2013 11
Products under Development for Bone Cancer - Comparative Analysis, H1 2013 12
Number of Products under Development by Companies, H1 2013 14
Number of Products under Development by Companies, H1 2013 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2013 17
Comparative Analysis by Late Stage Development, H1 2013 18
Comparative Analysis by Mid Clinical Stage Development, H1 2013 19
Comparative Analysis by Early Clinical Stage Development, H1 2013 20
Comparative Analysis by Discovery and Pre -Clinical Stage Development, H1 2013 21
Products under Development by Companies, H1 2013 22
Products under Development by Companies, H1 2013 (Contd..1) 23
Products under Investigation by Universities/Institutes, H1 2013 24
Celsion Corporation, H1 2013 25
Amgen Inc., H1 2013 26
Merck & Co., Inc., H1 2013 27
Exelixis, Inc., H1 2013 28
Bayer AG, H1 2013 29
Medivir AB, H1 2013 30
Osteologix, Inc., H1 2013 31
Green Cross Corporation, H1 2013 32
Merrion Pharmaceuticals Plc, H1 2013 33
Digna Biotech, S.L., H1 2013 34
Debiopharm Group, H1 2013 35
Amura Holdings Ltd., H1 2013 36
Alethia Biotherapeutics Inc., H1 2013 37
Hawthorn Pharmaceuticals, Inc., H1 2013 38
Deciphera Pharmaceuticals, LLC, H1 2013 39
Virobay Inc., H1 2013 40
Targa Therapeutics Corp., H1 2013 41
Assessment by Monotherapy Products, H1 2013 42
Assessment by Combination Products, H1 2013 43
Assessment by Stage and Route of Administration, H1 2013 45
Assessment by Stage and Molecule Type, H1 2013 47
Bone Cancer Therapeutics - Drug Profile Updates 106
Bone Cancer Therapeutics - Discontinued Products 151
Bone Cancer Therapeutics - Dormant Products 152
Bone Cancer Therapeutics - Dormant Products (Contd..1) 153
Bone Cancer Therapeutics - Dormant Products (Contd..2) 154

List of Chart


Number of Products under Development for Bone Cancer, H1 2013 11
Products under Development for Bone Cancer - Comparative Analysis, H1 2013 12
Products under Development by Companies, H1 2013 13
Products under Investigation by Universities/Institutes, H1 2013 16
Late Stage Products, H1 2013 18
Mid Clinical Stage Products, H1 2013 19
Early Clinical Stage Products, H1 2013 20
Discovery and Pre -Clinical Stage Products, H1 2013 21
Assessment by Monotherapy Products, H1 2013 42
Assessment by Combination Products, H1 2013 43
Assessment by Route of Administration, H1 2013 44
Assessment by Stage and Route of Administration, H1 2013 45
Assessment by Molecule Type, H1 2013 46
Assessment by Stage and Molecule Type, H1 2013 47

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *